A Phase 1 to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZP-3813, a Novel, Small Peptide Growth Hormone Receptor Antagonist, in Healthy Subjects

Soraya Allas, Thibaud Weiler, Guillaume Ravel, Colm Farrell, Sophie Fillon, Taha Ould Rouis, Michael D. Culler, Michel Ovize, Mark Sumeray, Aart Jan van der Lely

ENDO2024

CONFLICT OF INTEREST

Soraya Allas

☒ **I have the following potential conflicts of interest to report**:

- ☐ Research Contracts
- ☐ Consulting
- ☒ Employment in the Industry – Amolyt Pharma
- ☐ Stockholder of a healthcare company
- ☐ Owner of a healthcare company
- ☐ Other(s)

☐ **I declare that I have no potential conflict of interest.**



INTRODUCTION

- Acromegaly
  - Rare disease caused by the hypersecretion of GH from a pituitary tumor which in-turn stimulates the over production of IGF-1 from the liver
  - Treatment with somastostain analogs (SSA) monotherapy does not provide optimal control of serum IGF-1 levels in most patients
- AZP-3813
  - Novel, 16 amino acid peptide GH receptor antagonist
  - Long half-life
  - Being developped for the treament of acromegaly in patients insufficiently controlled with SSAs

STUDY DESIGN & SUBJECTS



Single Ascending Dose
N=8, 6 active + 2 placebo
*3 active + 2 placebo

Multiple Ascending Dose
N=8, 6 active + 2 placebo
14 days of administration

Sequential cohorts were administered ascending doses of AZP-3813 or placebo by SC injection in the abdominal wall

Study Population

- Healthy Male or Female subjects of nonchildbearing potential
- Age: 18 to 65 years inclusive
- BMI: 19 to 28 kg/m^2

Study Endpoints

- Safety and Tolerability
- Pharmacokinetics
- Pharmacodynamics: serum IGF-1 levels

AMOLYT PHARMA

PHARMACOKINETICS

Mean AZP-3813 Plasma Concentrations ± SEM (ng/mL)



- Cmax and AUC increased in a dose proportionnal manner.
- Half life ($t_{1/2}$) ~ 20-22h consistent with Once a Day dosing.
- Accumulation ratio equal to 1,75.

MEAN % CHANGE FROM BASELINE IN SERUM IGF-1

SINGLE ASCENDING DOSE



MULTIPLE ASCENDING DOSE



- Rapid dose related decrease IGF-1 levels at dose of 10 mg and above
- More prolonged reduction at higher doses (at 120 mg up to 72 hours)

- Gradual decrease in IGF-1
- Greater effect after 14 days compared to single administration, consistent with a cumulative effect following repeated administration
- Maximum % change from baseline adjusted to placebo ~ 50%

CONCLUSION

- Good tolerability with no safety concerns
- The half life ($t_{1/2}$) of AZP-3813 was estimated to be 20-22 hours
- Repeated administration of AZP-3813 induced a gradual and sustained dose-related decrease in IGF-1 levels consistent with a cumulative effect
- Collectively, the data support further testing in patients with acromegaly.

AMOLYT PHARMA


THANK YOU!
Pont Bonaparte, Lyon